Clorox (CLX) PT Lowered to $195 at Jefferies

Go back to Clorox (CLX) PT Lowered to $195 at Jefferies

Pre-Open Stock Movers 05/03: (MDP) (OCGN) (VIRX) Higher; (VXRT) (PETS) (EL) Lower (more...)

May 3, 2021 9:30 AM EDT

Today's Pre-Open Stock Movers

Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) 33% HIGHER; adds to recent momentum gains.

Meredith Corporation (NYSE: MDP) 12.5% HIGHER; today announced that it has agreed to sell its Local Media Group ("LMG") to Gray Television, Inc. (NYSE: GTN) for $2.7 billion in cash and will focus exclusively on its... More

Wells Fargo Downgrades Clorox (CLX) Two-Notches to 'Underweight', Calls 'Dead Money' at Best

May 3, 2021 8:21 AM EDT

Wells Fargo analyst Chris Carey downgrade the Clorox Company (NYSE: CLX) to Underweight from Overweight after the company slashed its 2022 guidance.

CLX stock closed over 3% lower last week after forecasting narrowing margins this year while revenues missed expectations. Quarterly sales came in at $1.78 billion to miss on the $1.86 billion projected by analysts.

Well activate our long-standing cost savings program and ensure that were delivering that across our businesses. Were looking at price increases, although were being very measured and taking that in a category-by-category approach and,... More

Clorox (CLX) PT Lowered to $177 at DA Davidson

May 3, 2021 7:28 AM EDT

DA Davidson analyst Linda Bolton Weiser lowered the price target on Clorox (NYSE: CLX) to $177.00 (from $189.00) while maintaining a Neutral rating.

The analyst commented, "CLX reported a F3Q21 EPS upside surprise, but missed consensus sales expectations, with Health & Wellness -8%... More

Clorox (CLX) PT Lowered to $186 at Deutsche Bank

May 3, 2021 6:51 AM EDT

Deutsche Bank analyst Stephen Powers lowered the price target on Clorox (NYSE: CLX) to $186.00 (from $195.00) while maintaining a Hold rating.... More

Wells Fargo Downgrades Clorox (CLX) to Underweight; 'Dead Money at Best'

May 3, 2021 6:31 AM EDT

(Updated - May 3, 2021 6:39 AM EDT)

Wells Fargo analyst Chris Carey downgraded Clorox (NYSE: CLX) from Overweight to Underweight, PT $170 (from $240.00).

The analyst comments "We are downgrading shares of CLX to Underweight from Overweight and lowering our price target to $170... More

Clorox (CLX) PT Lowered to $219 at Citi

May 3, 2021 5:17 AM EDT

Citi analyst Wendy Nicholson lowered the price target on Clorox (NYSE: CLX) to $219.00 (from $249.00) while maintaining a Buy rating.... More

Clorox (CLX) PT Lowered to $185 at Credit Suisse

May 3, 2021 5:14 AM EDT

Credit Suisse analyst Kaumil Gajrawala lowered the price target on Clorox (NYSE: CLX) to $185.00 (from $205.00) while maintaining a Neutral rating.... More

Clorox (CLX) PT Lowered to $170 at Morgan Stanley

May 3, 2021 4:08 AM EDT

Morgan Stanley analyst Dara Mohsenian lowered the price target on Clorox (NYSE: CLX) to $170.00 (from $183.00) while maintaining a Underweight rating.... More

Clorox (CLX) to raise prices on GLAD products in July - Bloomberg

April 30, 2021 1:47 PM EDT

Clorox (NYSE: CLX) to raise prices on GLAD products in July - Bloomberg

... More

Clorox (CLX) Tops Q3 EPS by 14c, Revenue Misses, Guides Below Consensus

April 30, 2021 6:38 AM EDT

Clorox (NYSE: CLX) reported Q3 EPS of $1.62, $0.14 better than the analyst estimate of $1.48. Revenue for the quarter came in at $1.78 billion versus the consensus estimate of $1.87 billion.

GUIDANCE:

Clorox sees FY2021 EPS of $7.45-$7.65, versus the consensus of $8.35.

10% to 13% sales growth (10% to 13% organic sales growth)$5.94 to $6.14 diluted EPS range (19% to 16% decrease versus year ago)$7.45 to $7.65 adjusted EPS range (1% to 4% increase versus year ago)Excludes the $2.11 loss from the noncash impairment related to the VMS business and the 60-cent one-time noncash gain from the Saudi JV acquisition... More